WTB RSS
01-27-2012, 07:08 PM
Merck KGaA ( MKGAF ) was recently buoyed by the news of European Commission ( EC ) approving its lead drug Rebif for the treatment of patients who have experienced a singlehttp://feedads.g.doubleclick.net/~a/X776i2kbi2IUI3ZLGo0M-pVg93g/0/di (http://feedads.g.doubleclick.net/~a/X776i2kbi2IUI3ZLGo0M-pVg93g/0/da)
http://feedads.g.doubleclick.net/~a/X776i2kbi2IUI3ZLGo0M-pVg93g/1/di (http://feedads.g.doubleclick.net/~a/X776i2kbi2IUI3ZLGo0M-pVg93g/1/da)
http://feeds.feedburner.com/~r/nasdaq/categories/~4/7XzcHW6LvmE
More... (http://articlefeeds.nasdaq.com/~r/nasdaq/categories/~3/7XzcHW6LvmE/label-expansion-for-merck-kgaa-drug-analyst-blog(2).aspx)
http://feedads.g.doubleclick.net/~a/X776i2kbi2IUI3ZLGo0M-pVg93g/1/di (http://feedads.g.doubleclick.net/~a/X776i2kbi2IUI3ZLGo0M-pVg93g/1/da)
http://feeds.feedburner.com/~r/nasdaq/categories/~4/7XzcHW6LvmE
More... (http://articlefeeds.nasdaq.com/~r/nasdaq/categories/~3/7XzcHW6LvmE/label-expansion-for-merck-kgaa-drug-analyst-blog(2).aspx)